IQVIA headquarters
An analysis from pharmaceutical research and data firm IQVIA projected the 340B program could more than double in size if patient eligibility expands.

Expanding 340B Eligibility Could Double Program Size, Says Report

The 340B program could more than double in size if the 340B patient definition expands, according to a recent report [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.